Tech Note

A Roadmap Towards Effective and Accessible Adoptive T Cell Manufacturing

In Cell and Gene Therapies, robust quality control is essential to meet regulatory standards and ensure product safety and efficacy. This note explores how the Accellix automated cartridge-based flow cytometry platform was evaluated for assessing CAR T cell identity and purity, comparing its performance with conventional flow cytometers. Using a lentiviral vector to express enhanced green fluorescent protein (eGFP) as a reporter gene, we demonstrated that Accellix’s platform can reliably support early-stage CGT manufacturing and quality control, offering a reproducible and efficient solution for critical process steps.

The collaboration showcases NecstGen’s role as a center of excellence for Cell and Gene Therapies, working alongside bioMérieux’s diagnostic expertise and Accellix’s innovative cytometry technology to enhance the manufacturing workflow for adoptive T cell therapies.

Read the full technical note to explore our findings and insights on leveraging advanced cytometry platforms for quality control in Cell and Gene Therapy.

Receive a copy by emailing us at bd@necstgen.com or leaving us a message.